The hypoxia inducible factor 1 (HIF-1) is a heterodimeric transcription factor which is an important regulator of growing tumor's response to hypoxia. It was reported that HIF-1 activates genes that allow the cancer cells to survive and grow in the hostile hypoxic tumor environment. Furthermore, the activity of HIF-1 has been shown to be central to regulation of apoptosis and cell survival, cell adhesion and extracellular matrix turnover, cytoskeletal structure, cell motility, epithelial homeostasis, vascular tonus, eythropoiesis and iron metabolism, metabolic homeostasis, and pH regulation.
HIF-1 is a heterodimeric protein that consists of a constitutively expressing nuclear-located β-subunit, also termed aryl hydrocarbon nuclear translocator (ARNT) and a O2-dependently regulated α-subunit.
1,2 Intratumoral hypoxia and genetic alterations can lead to HIF-1α over-expression. 3 In animal models, HIF-1α overexpression is associated with increased tumor growth, vascularization, and metastasis, whereas HIF-1α loss-of-function has the opposite effect; these findings validate HIF-1α as an attractive cancer drug target. 3, 4 Recently, considerable effort has been directed to the discovery of HIF-1 inhibitors, from chemical libraries and natural products. [5] [6] [7] These inhibitors reportedly regulate the HIF-1 signaling pathway through a variety of molecular mechanisms, including transcriptional regulation, folding, stabilization, nuclear translocation, degradation, and transactivation.
Our studies have been centred on development of small molecule HIF-1α inhibitors, including compounds 1-3, as potential a These authors equally contributed to this work.
anticancer agents (Fig. 1) . [8] [9] [10] [11] Of interest, these compounds were found from a structure-activity relationship study using a cell based HRE-Luc assay. Particularly, the 2-aminoisonicotinamide analogue 2 displayed potent inhibition of hypoxia-induced accumulation of HIF-1α protein in human cancer cell lines, in addition to a dose-dependent inhibition of HIF-1 target genes, such as VEGF. Herein, we present our focused structureactivity relationship study of HIF-1α inhibitors based on the isonicotinic moiety using human colorectal carcinoma cells HCT116.
The general routes for the synthesis of 2-aminoisonicotinic acid analogues are outlined in Schemes 1 and 2. As shown in Scheme 1, reaction of a variety of phenols 4-7 with ethyl chloroacetate followed by alkaline hydrolysis afforded the corresponding phenoxy acetic acid 8 in quantitative yield. Among the phenoxy acetic acid compounds, 4-admantanyl phenoxy acetic acid 8a was reacted with commercially available 2-amino isonicotinic methyl ester 9 and 2-aminoisonicotinamide 10 to yield compounds 11 and 2, respectively. Under same condition other phenoxy acetic acids 8b-d were coupled with 2-aminoisonicotinamide 10 to give the corresponding amide derivatives 12-14. Reaction of an ester analogue 11 in the presence of lithium iodide in pyridine produced the corresponding phenoxy acetic acid analogue 15, which was coupled with amines to give the corresponding amide derivatives 4a-f under PPAA and Et3N condition in good yields. Esterification of 15 with tert-butanol by using DCC and DMAP afforded compound 4h. As for preparation of 4i, intermediate 15 reacted with alkyl halide utilizing K 2 CO 3 and Cs 2 CO 3 to give compound 4i. Scheme 2 described synthetic procedure of ester derivatives possessing 2-aminoisonicotinate moiety. For synthesis of intermediates 16-19, commercially available 2-aminoisonicotinic acid was reacted with alkyl halides under basic condition. Analogues 4j-m were also readily obtained from 4-adamantyl phenoxy acetic acid 8a and the corresponding intermediates 16-19 in the presence of PPAA and Et 3 N.
The in vitro HIF inhibitory activities of 2-aminoisonicotinic acid analogues 2, 4a-m and 11-14 were evaluated using cell based HRE-Luc assay at two concentrations (1 μM and 10 μM), as shown in Table 1. 12 Topotecan, a known small-molecule HIF-1α inhibitor, was used as a reference compound for a comparision, which showed 56.9% of HRE-Luc activity at 3 μΜ. In this study, human colon cancer cells HCT116 was chosen because of its dramatic change in accumulation of HIF-1α protein 
Scheme 2
under hypoxia, in comparison with that in normoxic condition. In order to define the key structural requirements for HIF-1α inhibition of 2-aminoisonicotinic acid analogues, our optimization strategy was centered on two discrete areas: (1) the 2-aminoisonicotinic acid, which could be derivatived further and (2) the adamantyl phenyl ring which could be replaced by a phenyl ring with various groups. In view of the moderate inhibitory activity of the amide 2 (HRE-Luc activities; 97% at 1 μM, 43% at 10 μM) in cell based HRE-Luc assay using HCT116 cells, we first explored the effect of altering the amide group by preparing compounds 4a-g, in which dimethylamino, isopropylamino and morpholyl group attached via amide bond. Compound 4d (88% at 1 μM, 44% at 10 μM) and 4g (89% at 1 μM, 32% at 10 μM), linked through two carbon and three carbon chain, respectively, demonstrated considerable potency in HCT116, while 4a showed a marked decrease in inhibitory potency. The isoniconicotinic ester derivative 11 displayed considerable potent inhibition of HIF-1α. Encouraged by this, the impact of modification of the isonicotinic acid moiety was further extended to the analogue series characterized by an ester substitution. This derivatization produced ester analogues 4h-m, comprising ethyl and tert-butyl attached via ester group, in which 4h (48% at 1 μM, 41% at 10 μM) showed significant inhibitory activity. However, compounds 4i and 4k-m, linked through two carbon chain, exhibited poor inhibitory activity suggesting that the linker space is important for potency. Subsequently, we examined the effects of different aromatic substituents on the adamantyl phenyl ring, retaining the carboxylamide group at the meta position of pyridine ring. However, compounds 12-14 with various functionalities, including nitro, fluoro and proton, displayed poor inhibitory activity. Based on the initial in vitro HIF inhibitory assay, compound 4g was chosen as a representative compound for further study. Isonicotinamide analogue 4g showed the inhibitory activity in cell based HRE-Luc assay in a dose-dependent manner as shown in Figure 2A and its IC 50 was determined to 4.3 μM. In order to confirm its HIF inhibition, compound 4g was evaluated by Western blot analysis for its effect on hypoxia-induced HIF-1α accumulation. As shown in Figure 2B , the inhibitor 4g blocked HIF-1α accumulation dose-dependently in human carcinoma cancer cell lines HCT-116. HIF-1α responds to the hypoxia by binding to the HRE of target genes. Accordingly, the inhibitory effect of 4g on HIF-1α protein was analyzed via the expression of the downstream target genes VEGF and EPO, which are associated with the angiogenesis of an aggressive tumor. In the presence of 4g, the mRNA levels of VEGF and EPO in HCT 116 cells were decreased, while the mRNA expression level of the control GAPDH was not affected (Fig. 2C) . Further study is, however, warranted for more detailed mechanism of action of 4g on HIF-1α inhibition under hypoxia. Considering that poor pharmacokinetic properties accounted for many drug failures in development, our compound was tested for its drug-like property, i.e. cell permeability using Caco-2 cells, which are most commonly used in pharmaceutical study to predict cell absorption of drug candidate. As shown in Table 2 , 4g showed high permeability (P app values 22.9 × 10 6 cm/sec at 5 μM) compared with the positive control metoprolol (Papp values 27.2 × 10 6 cm/sec at 10 μM) and the negative control ranitidine (P app values 0.6 × 10 6 cm/sec, 20 μM) on Caco-2 cells. The high permeability of 4g may contribute to utility of this type of compounds for development of preclinical candidates. Encouraged by the biological activity and pharmacokinetic property, in vivo antitumor activity of 4g was further evaluated using nude mice and the human cancer cell line HCT116. The results were outlined in Figure 3 . When the mice were treated intravenously with 4g (30 mg/kg), tumor growth was inhibited by 51.3%, compared to the vehicle treated control group. Compound 4g did not cause any severe side effect, but the body weight decreased to 92.7%, which might be caused by minor adverse effect.
Notes
In summary, a series of 2-aminoisonicotinic acid analogues have been synthesized and their in vitro HIF-1 inhibitory activity was evaluated using cell based HRE-Luc assay in human colorectal carcinoma cells HCT116. Especially, compound 4g exhibited dose-dependent inhibition of HIF-1α, target gene expressions under hypoxia, favorable permeability, and potent in vivo efficacy. With these results in hand, further molecular mechanism studies are in progress, which will be reported in due course.
Experimental Section
General procedure for coupling reaction (4a-g and 4j-m) .
Compound 15 or 8a (1 equiv) was suspended in acetonitrile and Et 3 N (4.0 equiv), 50% PPAA (1.2 equiv) were added at room temperature. The reaction solution was stirred at room temperature for 30 min and the amine (1.2 equiv) was added. The reaction solution was stirred overnight and evaporated under reduced pressure. The residue was purified by column chromatography to obtain the products (4a-g and 4j-m) .
Other synthetic procedures and all spectral data of 2-aminoisonicotinic acid analogues can be found in supplementary material. The detailed in vitro and in vivo assay procedures were also shown in supporting information.
